Results of the economic evaluation of the first study - A multinational prospective economic evaluation

被引：40

作者：

Schulman, KA

Buxton, M

Glick, H

Sculpher, M

Guzman, G

Kong, J

Backhouse, M

Mauskopf, J

Bell, L

Eisenberg, JM

Califf, RM

McKenna, WJ

Harrell, FE

Uretsky, BF

Adams, KF

Swedberg, KB

Gheorghiade, M

Zannad, F

Handberg, E

Darius, H

SolerSoler, J

Wheeler, WS

Armstrong, PW

Patterson, H

Murali, S

Butman, S

Kirlin, PC

Miller, LW

Jafri, S

Rich, S

CostanzoNordin, MR

McGoon, M

Hosenpud, JD

Ratkovec, R

Brundage, B

Pritzker, M

Bourge, R

Reeves, W

Forgosh, L

Ventura, H

Young, JB

Mancini, D

Mills, RM

Limacher, MC

Lee, F

Revkin, J

Kalbfleisch, JM

Fishbein, D

Pressler, M

Haeusslein, E

机构：

[1] BRUNEL UNIV,HLTH ECON RES GRP,UXBRIDGE UB8 3PH,MIDDX,ENGLAND

[2] UNIV PENN,MED CTR,DIV GEN INTERNAL MED,PHILADELPHIA,PA 19104

[3] UNIV PENN,MED CTR,LEONARD DAVIS INST HLTH ECON,PHILADELPHIA,PA 19104

[4] SMITHKLINE BEECHAM PHARMACEUT CORP,LONDON,ENGLAND

[5] GLAXO WELLCOME INC,RES TRIANGLE PK,NC 27709

来源：

INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE | 1996年 / 12卷 / 04期

基金：

英国惠康基金;

关键词：

D O I：

10.1017/S0266462300010989

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

We present the prospective economic evaluation that served as a secondary endpoint for the FIRST study, a randomized international multicenter trial of patients with severe congestive heart failure. Although the clinical results of this study were disappointing, we demonstrated the feasibility of incorporating prospective economic evaluation in phase III clinical trials.

引用

页码：698 / 713

页数：16

共 23 条

[1]

BACKHOUSE MB, 1994, PHARMACOECONOMICS, V4, P358

[2]

*CAN COORD OFF HLT, 1994, GUID EC EV PHARM, P17

[3] EFFECT OF VASODILATOR THERAPY ON MORTALITY IN CHRONIC CONGESTIVE-HEART-FAILURE - RESULTS OF A VETERANS-ADMINISTRATION COOPERATIVE STUDY [J].

COHN, JN ;

ARCHIBALD, DG ;

ZIESCHE, S ;

FRANCIOSA, JA ;

HARSTON, WE ;

TRISTANI, FE ;

DUNKMAN, WB ;

JACOBS, W ;

FRANCIS, GS ;

FLOHR, KH ;

GOLDMAN, S ;

COBB, FR ;

SHAH, PM ;

SAUNDERS, R ;

FLETCHER, RD ;

LOEB, HS ;

HUGHES, VC ;

BAKER, B .

NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (24) :1547-1552

[4]

*COMM DEP HLTH HOU, 1992, GUID PHARM IND PREP

[5]

DRUMMOND MF, 1987, METHODS EVALUATION H

[6]

DUDLEY RA, 1993, J CLIN EPIDEMIOLOGY, V329, P546

[7]

EFRON B, 1987, J AM STAT ASSOC, V82, P171, DOI 10.2307/2289144

[8] A LEISURELY LOOK AT THE BOOTSTRAP, THE JACKKNIFE, AND CROSS-VALIDATION [J].

EFRON, B ;

GONG, G .

AMERICAN STATISTICIAN, 1983, 37 (01) :36-48

[9]

EISENBERG JM, 1989, PHARMACOEPIDEMIOLOGY, P469

[10] THE ANALYSIS OF CENSORED TREATMENT COST DATA IN ECONOMIC-EVALUATION [J].

FENN, P ;

MCGUIRE, A ;

PHILLIPS, V ;

BACKHOUSE, M ;

JONES, D .

MEDICAL CARE, 1995, 33 (08) :851-863

← 1 2 3 →